These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1907432)

  • 61. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.
    Peters H; Kieser M; Hölscher U
    Vasa; 1998 May; 27(2):106-10. PubMed ID: 9612115
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Assessment of flow and oxygen delivery to the lower extremity in arterial insufficiency: a PET-scan study comparison with other methods.
    Depairon M; Depresseux JC; Petermans J; Zicot M
    Angiology; 1991 Oct; 42(10):788-95. PubMed ID: 1952268
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Experiences with solcoseryl in treatment of stage II peripheral arterial occlusive disease--assessment of clinical effectiveness].
    Horsch S; Claeys L
    Vasa Suppl; 1992; 35():151-2. PubMed ID: 1481024
    [No Abstract]   [Full Text] [Related]  

  • 64. [Albatran: 3 years' experience with peripheral arteriopathies].
    Elbaz C
    Phlebologie; 1975; 28(4):611-7. PubMed ID: 1221446
    [No Abstract]   [Full Text] [Related]  

  • 65. Apparent failure of edetic acid chelation therapy for the treatment of coronary atherosclerosis.
    Wirebaugh SR; Geraets DR
    DICP; 1990 Jan; 24(1):22-5. PubMed ID: 2105562
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intermittent claudication--surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency.
    Lundgren F; Dahllöf AG; Lundholm K; Scherstén T; Volkmann R
    Ann Surg; 1989 Mar; 209(3):346-55. PubMed ID: 2647051
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Thrombolytic therapy in acute arterial occlusions].
    Ehringer H; Fischer M; Lechner K; Mayrhofer E
    Dtsch Med Wochenschr; 1970 Mar; 95(12):610-5 passim. PubMed ID: 5437712
    [No Abstract]   [Full Text] [Related]  

  • 68. Chelation therapy of atherosclerosis.
    Rathmann KL; Golightly LK
    Drug Intell Clin Pharm; 1984 Dec; 18(12):1000-3. PubMed ID: 6439540
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy.
    Circulation; 1989 Dec; 80(6):1544-8. PubMed ID: 2688971
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The PACK trial: morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications.
    Verstraete M
    Vasc Med; 1996; 1(2):135-40. PubMed ID: 9546928
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication].
    Blume J; Kieser M; Hölscher U
    Vasa; 1996; 25(3):265-74. PubMed ID: 8967154
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Failure of prostacyclin to improve peripheral arterial disease in dialysis patients.
    Ruggenenti P; Viganò G; Mecca G; Cassina G; Remuzzi G
    Nephron; 1990; 54(1):93-4. PubMed ID: 2104964
    [No Abstract]   [Full Text] [Related]  

  • 73. Exercise testing in lower-extremity arterial occlusive disease.
    Blackshear WM
    Cardiol Clin; 1984 Aug; 2(3):449-54. PubMed ID: 6242354
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Preprogrammed oscillations improve lower limb blood flow and walking distance in patients with peripheral arterial disease.
    Rabin I; Shpolanski U; Leibovitz A; Bass A
    Isr Med Assoc J; 2014 Jul; 16(7):423-6. PubMed ID: 25167687
    [TBL] [Abstract][Full Text] [Related]  

  • 75. EDTA chelation therapy.
    Lonsdale D
    Am J Surg; 1993 Sep; 166(3):316. PubMed ID: 8368447
    [No Abstract]   [Full Text] [Related]  

  • 76. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
    Belcaro G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The effect of oral trapidil therapy on clinical and hemorheological parameters in arteriosclerosis obliterans in comparison to pentoxifylline--a pilot study].
    Regenthal R; Voigt H; Reuter W; Preiss R
    Z Gesamte Inn Med; 1991 Apr; 46(6):185-90. PubMed ID: 2063598
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.
    Creager MA; Olin JW; Belch JJ; Moneta GL; Henry TD; Rajagopalan S; Annex BH; Hiatt WR
    Circulation; 2011 Oct; 124(16):1765-73. PubMed ID: 21947297
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical evaluation of satigrel in intermittent claudicators.
    Iwai T; Qian S
    Panminerva Med; 1996 Dec; 38(4):243-8. PubMed ID: 9063033
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increase of walking capacity after acute aminophylline administration in intermittent claudication.
    Picano E; Testa R; Pogliani M; Lattanzi F; Gaudio V; L'Abbate A
    Angiology; 1989 Dec; 40(12):1035-9. PubMed ID: 2596736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.